Literature DB >> 16547136

An L-RNA-based aquaretic agent that inhibits vasopressin in vivo.

Werner G Purschke1, Dirk Eulberg, Klaus Buchner, Stefan Vonhoff, Sven Klussmann.   

Abstract

A class of diuretic/aquaretic agents based on mirror-image oligonucleotides (so-called Spiegelmers) has been identified. These molecules directly bind and inhibit the neuropeptide vasopressin (AVP). AVP is the major regulatory component of body fluid homeostasis mediated through binding to the renal V(2) receptor. Elevated plasma levels of AVP are implicated in several pathological conditions, mainly cardiovascular diseases. In congestive heart failure, AVP is part of a neuroendocrine imbalance that is responsible for progressive worsening of the disease. Employing in vitro selection techniques, RNA aptamers that bind to the unnatural d-configuration of AVP were isolated. The best aptamer displayed an affinity to d-AVP of approximately 560 pM at 37 degrees C. The corresponding Spiegelmer, a 38-mer mirror-image oligonucleotide (l-RNA) termed NOX-F37, inhibits vasopressin-dependent activation of V(1a) as well as V(2) receptors with IC(50) values of 6.1 nM and 1 nM, respectively. NOX-F37 administered to healthy rats effectively neutralized AVP and increased diuresis dose-dependently for 24 h. The mode of action was strictly aquaretic, i.e., the increase in urine volume was not accompanied by an increase in electrolytes. These results clearly prove the in vivo efficacy of NOX-F37 and points out its potential as a drug in the treatment of diseases that are associated with body fluid overload.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16547136      PMCID: PMC1458813          DOI: 10.1073/pnas.0509663103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

1.  Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists.

Authors:  S B Paranjape; M Thibonnier
Journal:  Expert Opin Investig Drugs       Date:  2001-05       Impact factor: 6.206

2.  A DNA Spiegelmer to staphylococcal enterotoxin B.

Authors:  Werner G Purschke; Falko Radtke; Frank Kleinjung; Sven Klussmann
Journal:  Nucleic Acids Res       Date:  2003-06-15       Impact factor: 16.971

3.  OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.

Authors:  Y Yamamura; S Nakamura; S Itoh; T Hirano; T Onogawa; T Yamashita; Y Yamada; K Tsujimae; M Aoyama; K Kotosai; H Ogawa; H Yamashita; K Kondo; M Tominaga; G Tsujimoto; T Mori
Journal:  J Pharmacol Exp Ther       Date:  1998-12       Impact factor: 4.030

4.  Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor.

Authors:  J Fukuzawa; T Haneda; K Kikuchi
Journal:  Mol Cell Biochem       Date:  1999-05       Impact factor: 3.396

5.  Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia.

Authors:  Toshiki Miyazaki; Yoshitaka Yamamura; Toshiyuki Onogawa; Shigeki Nakamura; Shizuo Kinoshita; Sunao Nakayama; Hiroyuki Fujiki; Toyoki Mori
Journal:  Endocrinology       Date:  2005-04-14       Impact factor: 4.736

Review 6.  Gene regulation of vasopressin and vasopressin receptors in cancer.

Authors:  W G North
Journal:  Exp Physiol       Date:  2000-03       Impact factor: 2.969

Review 7.  Biologic rationale for the use of beta-blockers in the treatment of heart failure.

Authors:  Hani N Sabbah
Journal:  Heart Fail Rev       Date:  2004-04       Impact factor: 4.214

8.  VEGF(165) mediates glomerular endothelial repair.

Authors:  T Ostendorf; U Kunter; F Eitner; A Loos; H Regele; D Kerjaschki; D D Henninger; N Janjic; J Floege
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

Review 9.  Vasopressin antagonists in heart failure.

Authors:  Ladan Golestaneh; Ashok Talreja; Thierry H Le Jemtel
Journal:  Curr Heart Fail Rep       Date:  2004-12

10.  In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class.

Authors:  Britta Wlotzka; Susanne Leva; Bernd Eschgfäller; Jens Burmeister; Frank Kleinjung; Christine Kaduk; Peter Muhn; Holger Hess-Stumpp; Sven Klussmann
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-17       Impact factor: 11.205

View more
  17 in total

1.  Direct optical detection of viral nucleoprotein binding to an anti-influenza aptamer.

Authors:  Pierre Negri; Guojun Chen; Andreas Kage; Andreas Nitsche; Dieter Naumann; Bingqian Xu; Richard A Dluhy
Journal:  Anal Chem       Date:  2012-06-11       Impact factor: 6.986

2.  A novel C5a-neutralizing mirror-image (l-)aptamer prevents organ failure and improves survival in experimental sepsis.

Authors:  Kai Hoehlig; Christian Maasch; Nelli Shushakova; Klaus Buchner; Markus Huber-Lang; Werner G Purschke; Axel Vater; Sven Klussmann
Journal:  Mol Ther       Date:  2013-07-26       Impact factor: 11.454

3.  Integrated Microfluidic Aptasensor for Mass Spectrometric Detection of Vasopressin in Human Plasma Ultrafiltrate.

Authors:  J Yang; J Zhu; R Pei; J A Oliver; D W Landry; M N Stojanovic; Q Lin
Journal:  Anal Methods       Date:  2016-05-11       Impact factor: 2.896

4.  Label-free microfluidic characterization of temperature-dependent biomolecular interactions.

Authors:  Thaihuu Nguyen; Renjun Pei; Donald W Landry; Milan N Stojanovic; Qiao Lin
Journal:  Biomicrofluidics       Date:  2011-08-17       Impact factor: 2.800

5.  Polyetheylenimine-polyplexes of Spiegelmer NOX-A50 directed against intracellular high mobility group protein A1 (HMGA1) reduce tumor growth in vivo.

Authors:  Christian Maasch; Axel Vater; Klaus Buchner; Werner G Purschke; Dirk Eulberg; Stefan Vonhoff; Sven Klussmann
Journal:  J Biol Chem       Date:  2010-10-20       Impact factor: 5.157

6.  Targeting complement component 5a promotes vascular integrity and limits airway remodeling.

Authors:  Mohammad A Khan; Christian Maasch; Axel Vater; Sven Klussmann; John Morser; Lawrence L Leung; Carl Atkinson; Stephen Tomlinson; Peter S Heeger; Mark R Nicolls
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

7.  Surface-enhanced Raman spectroscopy based quantitative bioassay on aptamer-functionalized nanopillars using large-area Raman mapping.

Authors:  Jaeyoung Yang; Mirko Palla; Filippo Giacomo Bosco; Tomas Rindzevicius; Tommy Sonne Alstrøm; Michael Stenbæk Schmidt; Anja Boisen; Jingyue Ju; Qiao Lin
Journal:  ACS Nano       Date:  2013-06-07       Impact factor: 15.881

8.  The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys.

Authors:  Frank Schwoebel; Lucas T van Eijk; Dirk Zboralski; Simone Sell; Klaus Buchner; Christian Maasch; Werner G Purschke; Martin Humphrey; Stefan Zöllner; Dirk Eulberg; Frank Morich; Peter Pickkers; Sven Klussmann
Journal:  Blood       Date:  2013-01-24       Impact factor: 22.113

9.  Aptamer based surface enhanced Raman scattering detection of vasopressin using multilayer nanotube arrays.

Authors:  Yun Suk Huh; David Erickson
Journal:  Biosens Bioelectron       Date:  2009-10-07       Impact factor: 10.618

10.  Mathematical Model for Biomolecular Quantification Using Large-Area Surface-Enhanced Raman Spectroscopy Mapping.

Authors:  Mirkó Palla; Filippo G Bosco; Jaeyoung Yang; Tomas Rindzevicius; Tommy S Alstrom; Michael S Schmidt; Qiao Lin; Jingyue Ju; Anja Boisen
Journal:  RSC Adv       Date:  2015-10-02       Impact factor: 3.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.